Members of CEPAC recently convened in Providence, RI to deliberate and vote on the evidence on the clinical effectiveness and comparative value of nonpharmacologic interventions for patients with treatment-resistant depression (read the press release). This meeting examined the evidence on four interventions: transcranial magnetic stimulation (TMS), electroconvulsive therapy (ECT), vagus nerve stimulation and cognitive behavioral […]
Read More
01/05/2012
— Independent appraisal committee votes that evidence is adequate to demonstrate clinical benefits of esketamine versus placebo, but concerns remain about the study criteria used to define treatment-resistant depression and the lack of longer-term data on esketamine’s safety and effectiveness — — Esketamine’s list price would require a 25-52% discount to reach a fair value-based […]
Read More
06/20/2019
— Midwest CEPAC to vote on overall value of esketamine during May 23 public meeting — BOSTON, May 9, 2019 – The Institute for Clinical and Economic Review (ICER) today released an Evidence Report assessing the comparative clinical effectiveness and value of esketamine (Spravato™, Janssen), a nasal spray approved by the FDA in March as a therapy […]
Read More
05/09/2019
Boston, Mass., June 2, 2015 – The Institute for Clinical and Economic Review (ICER) has posted the final report Integrating Behavioral Health into Primary Care and its accompanying action guides and policy brief to the CTAF and CEPAC websites. The report evaluates the evidence on the comparative clinical effectiveness and value of efforts to integrate […]
Read More
06/02/2015
Public Comments
Closed